Scholarlink

<p>Mutations in <i>PIK3R1</i> have recently been identified in patients with overgrowth syndromes and complex vascular malformations. <i>PIK3R1</i> encodes p85α which acts as the regulatory subunit of the lipid kinase PI3Kα. <i>PIK3R1</i> mutations result in the excessive activation of the AKT/mTOR pathway. Currently, there are no approved treatments specifically dedicated to patients with <i>PIK3R1</i> mutations, and medical care primarily focuses on managing symptoms. In this study, we identified three patients, including two children, who had mosaic somatic <i>PIK3R1</i> mutations affecting the iSH2 domain, along with severe associated symptoms that were unsuccessfully treated with rapamycin. We conducted in vitro experiments to investigate the impact of these mutations, including a double <i>PIK3R1</i> mutation in cis observed in one patient. Our findings revealed that p85α mutants in the iSH2 domain showed sensitivity to alpelisib, a pharmacological inhibitor of PI3Kα. Based on these findings, we received authorization to administer alpelisib to all three patients. Following drug introduction, patients rapidly demonstrated clinical improvement, pain, fatigue and inflammatory flares were attenuated. Magnetic Resonance Imaging showed a mean decrease of 22.67% in the volume of vascular malformations over twelve months of treatment with alpelisib. No drug-related adverse events were reported during the course of the study. In conclusion, this study provides support for the use of PI3Kα inhibition as a promising therapeutic approach for individuals with <i>PIK3R1</i>-related anomalies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Somatic PIK3R1 mutations in the iSH2 domain are accessible to PI3Kα inhibition

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月19日

查看全文
  • Gabriel Morin,
  • Alexandre P Garneau,
  • Nabiha Bouzakher,
  • Louise Ségot,
  • Antoine Fraissenon,
  • Amélie Blondel,
  • Florence Petit,
  • Caroline Chopinet,
  • Franck Mayeux,
  • Pierre Fayoux,
  • Anne Dompmartin,
  • Christine Bodemer,
  • Estelle Balducci,
  • Sophie Kaltenbach,
  • Patrick Villarese,
  • Vahid Asnafi,
  • Christophe Legendre,
  • Christine Broissand,
  • Sylvie Fraitag,
  • Chloé Quelin,
  • Nicolas Goudin,
  • Laurent Guibaud,
  • Guillaume Canaud

摘要

Mutations in PIK3R1 have recently been identified in patients with overgrowth syndromes and complex vascular malformations. PIK3R1 encodes p85α which acts as the regulatory subunit of the lipid kinase PI3Kα. PIK3R1 mutations result in the excessive activation of the AKT/mTOR pathway. Currently, there are no approved treatments specifically dedicated to patients with PIK3R1 mutations, and medical care primarily focuses on managing symptoms. In this study, we identified three patients, including two children, who had mosaic somatic PIK3R1 mutations affecting the iSH2 domain, along with severe associated symptoms that were unsuccessfully treated with rapamycin. We conducted in vitro experiments to investigate the impact of these mutations, including a double PIK3R1 mutation in cis observed in one patient. Our findings revealed that p85α mutants in the iSH2 domain showed sensitivity to alpelisib, a pharmacological inhibitor of PI3Kα. Based on these findings, we received authorization to administer alpelisib to all three patients. Following drug introduction, patients rapidly demonstrated clinical improvement, pain, fatigue and inflammatory flares were attenuated. Magnetic Resonance Imaging showed a mean decrease of 22.67% in the volume of vascular malformations over twelve months of treatment with alpelisib. No drug-related adverse events were reported during the course of the study. In conclusion, this study provides support for the use of PI3Kα inhibition as a promising therapeutic approach for individuals with PIK3R1-related anomalies.